Europese Unie - Nederlands - EMA (European Medicines Agency)

elanco gmbh - levende niet-pathogene escherichia coli o141: k94 (f18ac) en o8: k87 (f4ac) - immunologicals for suidae, live bacterial vaccines - varkens - voor actieve immunisatie van varkens vanaf 18 dagen tegen enterotoxigene f4-positieve en f18-positieve escherichia coli om de incidentie van matige tot ernstige post-spenen e te verminderen. coli diarree (pwd) bij geïnfecteerde varkens en om de fecale uitscheiding van enterotoxigene f4-positieve en f18-positieve e te verminderen. coli van geïnfecteerde varkens.

Europese Unie - Nederlands - EMA (European Medicines Agency)

zoetis belgium sa - varkens circovirus recombinant virus (cpcv) 1-2, geïnactiveerd - immunologische - varkens (biggen) - actieve immunisatie van varkens vanaf de leeftijd van drie weken tegen porciene circovirus type 2 (pcv2) reductie van de viral load in het bloed en de lymfoïde weefsels, en de laesies in de lymfoïde weefsels geassocieerd met pcv2 infectie, evenals het verminderen van klinische symptomen - met inbegrip van het verlies van de dagelijkse gewichtstoename, en sterfte geassocieerd met post-weaning multisystemic wasting syndrome).

Europese Unie - Nederlands - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals voor suidae - varkens (voor de mesterij) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

boehringer ingelheim vetmedica gmbh - levend porcine reproductief en respiratoir syndroom virus - lyofilisaat voor suspensie voor injectie - porcine reproductive and respiratory syndrome (prrs) virus vaccine - varkens

Europese Unie - Nederlands - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - varkens - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

intervet nederland b.v. - levend verzwakt porcine reproductief en respiratoir syndroom (prrs) virus, stam dv - lyofilisaat voor suspensie voor injectie - porcine reproductive and respiratory syndrome (prrs) virus vaccine - varkens

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

boehringer ingelheim vetmedica gmbh - levend verzwakt porcine reproductief en respiratoir syndroom (prrs) virus, stam 94881 - lyofilisaat voor suspensie voor injectie - porcine reproductive and respiratory syndrome (prrs) virus vaccine - varkens

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

boehringer ingelheim vetmedica gmbh - levend verzwakt porcine reproductief en respiratoir syndroom (prrs) virus, stam 94881 - lyofilisaat voor suspensie voor injectie - porcine reproductive and respiratory syndrome (prrs) virus vaccine - varkens

Nederland - Nederlands - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

laboratorios hipra s.a. - levend verzwakt porcine reproductief en respiratoir syndroom (prrs) virus, stam vp-046 bis - lyofilisaat voor suspensie voor injectie - porcine reproductive and respiratory syndrome (prrs) virus vaccine - varkens

Europese Unie - Nederlands - EMA (European Medicines Agency)

intervet international b.v. - varkenscircovirus type 2 orf2 subeenheid antigeen - immunologicals for suidae, inactivated viral vaccines - varkens - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by pcv2 infection.  to reduce loss of daily weight gain and mortality associated with pcv2 infection.